Healthcare / Diagnostics & ResearchASX
$0.35
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-677882.00 · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$19M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-18.2%
↓Gross Margin
100.0%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.2%
FCF CAGR
—
FCF margin
-2.3%
FCF / Net income
0.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $29.0M · net income $-2.9M · FCF $-677882.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $29.0M | $29.0M | $26.4M | $19.7M | $17.1M |
| Net Income | $-2.9M | $-2.9M | $-2.6M | $-4.2M | $-3.0M |
| EBITDA | $-452639.00 | $-452639.00 | $45579.00 | $-1.3M | $-748857.00 |
| EPS | -0.06 | -0.06 | -0.06 | -0.10 | -0.09 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -3.1% | -3.1% | -8.4% | -13.2% | -14.8% |
| Net Margin | -9.9% | -9.9% | -9.9% | -21.3% | -17.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.08 | 0.08 | 0.07 |
| Current Ratio | 1.73 | 1.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-677882.00 | $-677882.00 | $-2.8M | $414592.00 | $-4.2M |
| Returns | |||||
| ROE | -18.2% | -18.2% | -18.1% | -26.2% | -19.1% |
| Valuation | |||||
| EV/EBITDA | — | — | 358.20 | — | — |
| P/B | 1.13 | 1.13 | 1.19 | 1.67 | 1.12 |
| Growth & Yield | |||||
| Revenue Growth | 9.5% | 9.5% | 34.5% | 14.9% | — |
| EPS Growth | 3.6% | 3.6% | 41.8% | -17.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.06 → -0.06
Residual
+7.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.